Outcome-based payment could be future of CRO industry; AstraZeneca signs on with web-based outsourcing service;

 @DamianFierce: Covance took a $12.7M loss in the second quarter, but analysts are still optimistic about the company's future. More | Follow @DamianFierce

> Outcome-based payment for CROs may be the future of the industry, according to one strategic outsourcing firm. News

> AstraZeneca ($AZN) has signed on to use Assay Depot, an Internet database that unites pharmas and contractors. Article

> Cleveland's ImageIQ has secured a contract with Histogenics to provide imaging analytics for a Phase II trial of the company's NeoCart implant. More

> Clinical trials conducted by drugmakers may be biased, a federal group says, as companies sometimes deliberately compare new treatments to inferior drugs. Story

> GVK Biosciences has cleared an FDA audit of its Ahmedabad Clinical Pharmacology Unit, a 110-bed facility in India. Release

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.